Investment Thesis
Pre-revenue pharmaceutical company with severe operating losses (-$130.4M) and no revenue generation, indicating early-stage development status. While maintaining strong liquidity ($273.1M cash, 7.41x current ratio) and zero debt provide ~1.8 year operational runway, the company is destroying shareholder value with negative ROE of -100.8% and ROA of -28.0%.
Strengths
- Strong cash position of $273.1M representing 58% of total assets
- Excellent liquidity with 7.41x current ratio and no long-term debt obligations
- Zero leverage (0.00 debt/equity) provides financial flexibility for operations and future financing
Risks
- Absent revenue generation with no sales reported despite pharmaceutical sector classification
- Operating cash burn of -$149.9M annually provides approximately 1.8 year runway at current rate
- Persistent negative profitability destroying shareholder equity with -100.8% ROE and -28.0% ROA
Key Metrics to Watch
- Clinical trial progression and FDA approval timeline for pipeline candidates
- Quarterly operating cash burn trajectory to assess runway extension or compression
- Revenue realization date and initial sales volumes from approved indications
Financial Metrics
Revenue
N/A
Net Income
-130.5M
EPS (Diluted)
$-0.88
Free Cash Flow
-149.9M
Total Assets
466.4M
Cash
273.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-100.8%
ROA
-28.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.41x
Quick Ratio
7.41x
Debt/Equity
0.00x
Debt/Assets
72.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:56:42.088359 |
Data as of: 2026-03-31 |
Powered by Claude AI